Hematologic Malignancy
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
20 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 22 trials with date data
Clinical Trials (22)
Total enrollment: 1,182 patients across 22 trials
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
VitalTraq for the Detection of CRS
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Remote Temperature Data for Early Detection of Febrile Neutropenia
Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.